Arvinas, Inc. (NASDAQ:ARVN) is among the best US stocks under $10 to invest in. XTX Topco Ltd has increased its stake in ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

There's been a notable change in appetite for Arvinas, Inc. (NASDAQ:ARVN) shares in the week since its quarterly report, with the stock down 15% to US$6.29. Revenue was dismal, with revenues of US$22m ...

Q2 2025 Management View John G. Houston, Chairperson, CEO & President, stated the quarter was eventful with "significant clinical and regulatory programs across our pipeline of PROTAC degraders." He ...

The global Targeted Protein Degradation Market, valued at US$0.01 billion in 2024, stood at US$0.48 billion in 2025 and is ...

Arvinas Inc. Annual stock financials by MarketWatch. View the latest ARVN financial statements, income statements and financial ratios.

For example, Arvinas, Inc. (NASDAQ:ARVN) shareholders have seen the share price rise 80% over three years, well in excess of the market return (41%, not including dividends).

Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. Contacts Investors: Jeff Boyle +1 (347) 247-5089 ...

Arvinas has also granted the underwriters a 30-day option to buy an additional 857,142 shares at the public offering price. The $400 million offering is expected to close on Friday, subject to ...

Shares of Arvinas (ARVN -2.02%) rallied nearly 10% during Thursday's trading session, in response to the announcement of a new collaboration with drug giant Pfizer (PFE -0.04%).

Arvinas on Wednesday said Houston, who has been president and chief executive of the New Haven, Conn., company since September 2017, will retire from those positions upon the appointment of a ...

The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, reached an all-time high of $108 in July of this year ...